Drug Metabolism

Drug metabolism refers to the biochemical modification of pharmaceutical substances by living organisms, primarily through enzymatic processes in the liver. It plays a critical role in determining a drug's efficacy, duration of action, and potential toxicity. Understanding drug metabolism helps researchers optimize dosage regimens, predict drug–drug interactions, and design safer, more effective therapeutics during pharmaceutical development.

The cytochrome P450 (CYP450) enzyme family—especially isoforms like CYP3A4, CYP2D6, CYP2C9, and CYP2C19—are the primary enzymes responsible for phase I drug metabolism in the human liver. These enzymes catalyze oxidation, reduction, and hydrolysis reactions that convert lipophilic drugs into more water-soluble metabolites for excretion. Phase II metabolism involves conjugation enzymes such as UDP-glucuronosyltransferases (UGTs), sulfotransferases (SULTs), and glutathione S-transferases (GSTs).

Genetic polymorphisms in drug-metabolizing enzymes—particularly in CYP450 genes—can lead to significant interindividual differences in drug response. For example, individuals may be classified as poor, intermediate, extensive, or ultrarapid metabolizers based on their CYP2D6 genotype. These variations influence drug clearance rates, therapeutic outcomes, and risk of adverse effects, making pharmacogenomic testing valuable in personalized medicine and dose optimization.

Drug metabolism occurs in two main phases:• Phase I: Involves functionalization reactions (e.g., oxidation, reduction, hydrolysis) that introduce or expose polar groups on the drug molecule, often mediated by CYP450 enzymes.• Phase II: Consists of conjugation reactions (e.g., glucuronidation, sulfation, acetylation) that attach endogenous molecules to increase water solubility and facilitate renal or biliary excretion.Some drugs undergo only one phase, while others progress through both.

Regulatory agencies like the FDA and EMA require comprehensive drug metabolism data as part of Investigational New Drug (IND) and New Drug Application (NDA) submissions. These studies identify major metabolic pathways, active or toxic metabolites, enzyme involvement, and potential drug–drug interactions. Such information ensures patient safety, informs labeling recommendations, and supports clinical trial design—key factors in gaining regulatory approval for new pharmaceuticals.